# Safety and Immunogenicity of a Hantaan Virus DNA Vaccine and a Puumala Virus DNA Vaccine, For The Prevention of Hemorrhagic Fever With Renal Syndrome

> **NCT04333459** · PHASE2 · UNKNOWN · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 132 (estimated)

## Conditions studied

- Hantaan Virus Nephropathy
- Puumala Virus Nephropathy

## Interventions

- **BIOLOGICAL:** Hataan DNA Vaccine/Puumala DNA Vaccine

## Key facts

- **NCT ID:** NCT04333459
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-23
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04333459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04333459, "Safety and Immunogenicity of a Hantaan Virus DNA Vaccine and a Puumala Virus DNA Vaccine, For The Prevention of Hemorrhagic Fever With Renal Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04333459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*